Folliculitis decalvans



Folliculitis decalvans


Andrew J.G. McDonagh


Evidence Levels:  A Double-blind study  B Clinical trial ≥ 20 subjects  C Clinical trial < 20 subjects  D Series ≥ 5 subjects  E Anecdotal case reports


image


Folliculitis decalvans is a rare progressive purulent folliculitis of the scalp resulting in follicular atrophy and subsequent scarring alopecia. ‘Tufted folliculitis’ is a characteristic of the disorder in evolution, with multiple hair tufts emerging from inflamed and crusted follicular orifices.


The etiology is unknown. Impaired immune responses, Staphylococcus aureus infection, nevoid lesions, and seborrheic states have been suggested as playing a role in its pathogenesis, though much controversy surrounds the role of each factor. Gram-positive organisms are usually present during active disease phases.


Folliculitis ‘decalvans’ may affect any hair-bearing region, i.e., scalp, face, axillae, pubes, and inner thighs. Scalp disease affects both sexes. In other sites it is confined to adult males. It occurs predominantly in men from adolescence onwards, and in women between the third and sixth decades.



Management strategy


Treatment of this chronic and progressive disease is notoriously difficult. Underlying diseases such as immunodeficiency or fungal infection should be sought. Staphylococcus aureus or other Gram-positive organisms are present in follicular pustules and sometimes also in the anterior nares. Bacteriology swabs should be taken for culture and to determine sensitivity.


Topical and systemic antibiotics are the mainstay of treatment. Systemic antibiotics such as tetracycline, minocycline, flucloxacillin, and third-generation cephalosporins may inhibit the extension of disease, but only for as long as they are administered. Rifampin has been proposed as the most beneficial therapeutic option in recalcitrant cases, but should not be used as monotherapy because of the rapid emergence of resistance. A regimen of systemic rifampin 300 mg twice daily and clindamycin 300 mg twice daily for 10 weeks has produced marked improvement, with infrequent relapse after one or more treatment courses. Prolonged courses of dapsone can also be beneficial.


Systemic corticosteroids suppress the inflammatory response and may provide moderate temporary improvement. There have been anecdotal reports of success using oral zinc sulfate (in combination with fusidic acid). Treatments that destroy hair follicles and prevent hair regrowth may be considered; these include X-ray epilation, laser epilation, cryosurgery, and surgical excision. Improvement has also been reported with shaving the scalp. Keratolytics and tar shampoos may reduce the scaling and erythema that herald extension of the disease. There is a single published report of response to anti-TNF therapy with infliximab.



Specific investigations











Related posts:

Cat scratch disease Hemangiomas Tinea capitis Necrolytic migratory erythema Nevoid basal cell carcinoma syndrome Rocky Mountain spotted fever and other rickettsial infections

Stay updated, free articles. Join our Telegram channel
Tags:
Aug 7, 2016 | Posted by in Dermatology | Comments Off on Folliculitis decalvans

Full access? Get Clinical Tree
Get Clinical Tree app for offline access